Product Description
alpha-2c adrenoceptor antagonist (Sourced from: https://www.orion.fi/en/Orion-group/media/stock-exchange-releases/2014/orion-group-financial-statement-release-for-2013/)
Mechanisms of Action: ADRA2C Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Orion Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT01839019 | P1 |
Completed |
Healthy Volunteers |
2013-06-01 |